NCT06710132进行中（未招募）1 期
PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 184
- 试验地点
- 163
- 主要终点
- Substudies GC/NSCLC/PDAC: Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigators
研究概览
简要总结
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the antitumor activity, tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combination treatments in adult participants with locally advanced/metastatic CEACAM5 expressing tumors. There will be 3 substudies under this Master Protocol that may be conducted in parallel.
- PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Gastric Cancer (Substudy GC);
- PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Non-Small Cell Lung Cancer (Substudy NSCLC);
- PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC).
详细描述
The study follows a master protocol concept with several separate substudies in specific indications.
- Substudy GC: The study duration per participant is on an average approximately 10 months. This includes a 28-day Screening period, infusion (approximately 1 hour) on Day 1 of every cycle, and Safety Follow-up Visit 30 (± 3) days after the last dose of M9140.
- Substudy NSCLC: Study duration per participant is approximately 12 months. This includes a 28-day Screening period, infusion (approximately 1 hour) on Day 1 of every cycle, and Safety Follow-up Visit 30 (± 3) days after the last dose of M9140.
- Substudy PDAC: Study duration per participant is on an average approximately 8 months. This includes a 28-day Screening period, infusion (approximately 1 hour) on Day 1 of every cycle, and Safety Follow-up Visit 30 (±3) days after the last dose of M9140.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants are capable of signing informed consent as defined in protocol
- •Eastern Cooperative Oncology Group Performance Status (ECOG PS) below or equal to 1
- •Participants with adequate hematologic, hepatic and renal function as defined in protocol
- •Participant must have at least 1 lesion that is measurable using RECIST v1.
- •Other protocol defined inclusion criteria could apply
- •Substudy GC:
- •Participants in Part A and Part B with documented histopathological diagnosis of advanced or metastatic, HER2 negative, gastric or GEJ (with an epicenter 2 centimeter (cm) proximal or distal to the GEJ) adenocarcinoma, who were intolerant/refractory to or progressed after systemic therapies for the advanced/metastatic stage that must have included (provided there is no medical contraindication and these agents are locally approved and available) a fluoropyrimidine and a platinum agent and an Immune checkpoint inhibitors (ICI) for participants with a known microsatellite instability-high (MSI-H) status or participants whose tumor express PD-L1 with a CPS greater than or equal (>=) 1
- •Participants must have received and progressed (according to RECIST 1.1) on at least 1 line of therapy for the treatment of advanced/metastatic disease but no more than 2
- •Participants in Part A with CEACAM5high GC/GEJC (defined as IHC >= 2+ staining in >= 50% of tumor cells)
- •Participants in Part B with CEACAM5low GC/GEJC (defined as IHC >= 2+ staining in less than (<) 50% of tumor cells)
- •Other protocol defined inclusion criteria could apply
- •Substudy NSCLC:
- •Participants in Part A and Part B with histologically or cytologically documented advanced (Stage III not eligible for resection or curative radiation) or metastatic NSCLC with or without driver genomic alterations
- •Participants must have been intolerant/refractory to or progressed after systemic therapies for the advanced/metastatic stage
- •Participants must have received and progressed (according to RECIST 1.1) on at least 1 line of therapy for the treatment of advanced/metastatic disease but no more than 3
- •Participants who received a platinum-containing regimen or a targeted therapy as (neo)-adjuvant therapy for early-stage disease, if relapse or metastases occurred during or within 3 months after regimen completion, are considered to have received a line of treatment in the advanced setting
- •Participants in Part A with CEACAM5 high-expressing EGFR tumors (including participants with any driver genomic alterations other than EGFR mutations
- •Participants in Part B with CEACAM5 high known EGFR mutated tumors as assessed according to local clinical practice
- •Other protocol defined inclusion criteria could apply
- •Substudy PDAC:
- •Participants with histologically or cytologically confirmed advanced or metastatic PDAC, who were intolerant/refractory to or progressed after systemic therapies for the advanced metastatic stage that must have included (provided there is no medical contraindications, and these agents are locally approved and available; FOLFIRINOX regimen or NALIRIFNOX regimen or Nab-paclitaxel/gemcitabine regimen
- •Participants must have received and progressed (according to RECIST 1.1) on at least one 1 line of therapy for the treatment of advanced/metastatic disease but no more than 2
- •All participants will be screened using an IHC test to define CEACAM5 expression. Only participants with CEACAM5high expressing tumors will be eligible
- •Other protocol defined inclusion criteria could apply
排除标准
- •Participant has a history of malignancy within 3 years before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, benign prostate neoplasm/hypertropia, or malignancy that in the opinion of the Investigator, with concurrence with the Sponsor's Medical Monitor, is considered cured with minimal risk of recurrence within 3 years)
- •Participants with known brain metastases, except those meeting the following criteria: Brain metastases that have been treated locally and are clinically stable for at least 4 weeks prior to the start of treatment; No ongoing neurological symptoms that are related to the brain localization of the disease (sequelae that are a consequence of the treatment of the brain metastases are acceptable)
- •Participants with diarrhea (liquid stool) or ileus Grade > 1
- •Participants with active chronic inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease, intestinal perforation) and/or bowel obstruction
- •Cardiac arrhythmia, unstable angina, myocardial infarction, congestive heart failure (New York Heart Association [NYHA] >= II) or a coronary revascularization procedure within 180 days of study entry. Calculated QTc average (using the Fridericia correction calculation) of > 470 milliseconds (ms)
- •Cerebrovascular accident/stroke (< 6 months prior to enrollment)
- •Other protocol defined exclusion criteria could apply
- •Substudy GC - Participants with prior therapy with irinotecan
- •Substudy NSCLC:
- •- Participants with prior therapy with irinotecan
- •Substudy PDAC: none
研究组 & 干预措施
Substudy PDAC: M9140 Monotherapy - Part A CEACAM5 High
Experimental
干预措施: M9140 (Drug)
Substudy GC: M9140 Monotherapy - Part A CEACAM5 High
Experimental
干预措施: M9140 (Drug)
Substudy GC: M9140 Monotherapy - Part B CEACAM5 Low
Experimental
干预措施: M9140 (Drug)
Substudy NSCLC: M9140 Monotherapy - Part A CEACAM5 High EGFR Wt
Experimental
干预措施: M9140 (Drug)
Substudy NSCLC: M9140 Monotherapy - Part B CEACAM5 High EGFR mut
Experimental
干预措施: M9140 (Drug)
结局指标
主要结局
Substudies GC/NSCLC/PDAC: Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigators
时间窗: Time from first study treatment to (planned) final assessment at approximately 48 months
次要结局
- Substudies GC/NSCLC/PDAC: Number of Participants with Adverse Events (AEs) and Treatment Related AEs(Time from first study treatment to (planned) final assessment at approximately 48 months)
- Substudies GC/NSCLC/PDAC: Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigators(Time from first study treatment to (planned) final assessment at approximately 48 months)
- Substudies GC/NSCLC/PDAC: Number of Participants with Disease Control(At Week 12)
- Substudies GC/NSCLC/PDAC: Time to Response according to RECIST v1.1 as Assessed by Investigators(Time from first study treatment to (planned) final assessment at approximately 48 months)
- Substudies GC/NSCLC/PDAC: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigators(Time from first study treatment throughout the study duration until progressive disease or death due to any cause, whichever occur first, approximately 48 months)
- Substudies GC/ NSCLC/ PDAC: Pharmacokinetic (PK) Plasma Concentrations of M9140(Cycle (C) 1 Day (D) 1 to C3D15, C4D1 and from C8D1 every 4 cycles on D1 until treatment discontinuation (each cycle is of 21 days), assessed up to approximately 12 months)
- Substudies GC/NSCLC/PDAC: Number of Participants with Anti-Drug Antibodies (ADA) Against M9140(Predose (C1D1, C3D1, C8D1) and end of study intervention, assessed up to approximately 12 months)
- Substudy GC: CEACAM5 expression in tumor(Day 1)
研究者
研究点 (163)
Loading locations...
相似试验
已完成
不适用
Tumor profiling in pancreatic carcinoma, a multidisciplinary initiativepancreatic carcinoma10017990pancreatic cancerNL-OMON35953Academisch Medisch Centrum200
招募中
1 期
Phase 2 Study of HER3-DXd in Locally Advanced or Metastatic Solid Tumorsocally Advanced or Metastatic Solid TumorsMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2023-507641-29-00Daiichi Sankyo Inc.120
终止
1 期
A Study of SGN-MesoC2 in Advanced Solid TumorsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsPancreatic AdenocarcinomaMesotheliomaOther Solid TumorsEndometrialColorectal NeoplasmsNCT06466187Seagen, a wholly owned subsidiary of Pfizer19
招募中
2 期
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 AlterationsSolid TumoursNCT06581432Boehringer Ingelheim588
招募中
不适用
Establishment of Pancreas Cancer and Cancer-associated Fibroblast Using EUS-guided Biopsy SamplesPancreas AdenocarcinomaNCT05571956Ajou University School of Medicine50